Administration of a small molecule Dnmt inhibitor has been shown to improve insulin sensitivity in the setting of obesity, in part by demethylating the Adipoq promoter, and a role for Dnmt1 in this process was suggested by genetic knockdown studies in cultured adipocytes (Kim et al., 2015). Here, DNMT1 is linked to obesity disorder.